Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in Italy
- First Online:
- 90 Downloads
Background: The reporting of adverse drug reactions (ADRs) is the mainstay of post-marketing surveillance systems. Under-reporting and selective reporting are considered the main limitations of a spontaneous reporting-based pharmacovigilance system. However, excessive reporting induced by external events may also impair signal detection by increasing the noise level.
Objective: The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors (‘statins’) and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors (‘coxibs’) and increase in cardiovascular risk.
Methods: The study was based on data from spontaneous reporting in six Italian regions collected from January 1995 to December 2005. We analysed a 10-year period as a reasonable time interval around the four situations of interest, highlighting the influence of regulatory measures on the rate of ADR reporting (number of reports per million inhabitants). Chi-squared tests were used to assess the statistical significance of any changes in ADR reporting. Drug sales data were also studied to examine possible changes in drug use. Sales data were expressed as daily defined dose per 1000 inhabitants per day.
Results: ACE inhibitors: a 5-fold increase in the reporting rate of ACE inhibitor-induced cough was observed in 1998 and 1999 following a restriction on reimbursement for angiotensin receptor blockers introduced in 1998 and removed at the end of 1999. Statins: after the withdrawal of cerivastatin in 2001, the ADR reporting rate increased more than 4-fold, with musculoskeletal ADRs representing about 60% of all the ADRs reported in that year, and progressively decreased in the following years. Nimesulide: an increase in hepatic ADR reporting was observed after withdrawal of the drug from the Finnish and Spanish markets in 2002. Coxibs: no important changes in the rate of cardiovascular events reporting in the period 2000–4 were observed. In 2005, after the withdrawal of rofecoxib in September 2004, both the ADR reporting rate and sales of the drug decreased drastically.
Conclusion: Our data suggest that spontaneous ADR reporting can be influenced in different ways by external events. Our data emphasize the need for educational initiatives aimed at increasing the doctor’s and patient’s awareness of the usefulness and the limitations of spontaneous reporting in the pharmacovigilance system. Such initiatives should use appropriate risk communication strategies in order to avoid unnecessary alarm, which could cause unjustified interruption of therapies or misplaced confidence in new drugs.
- 7.Gruppo Interegionale di Farmcovigilanza [online]. Available from URL: http://www.gruppogif.org [Accessed 2007 Sep 28]
- 11.European Medicines Agency (EMEA). Committee for Proprietary Medicinal Products (CPMP): opinion following an article 36 referral Cerivastatin CPMP/3962/02 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/referral/Cerivastatin/396202en.pdf [Accessed 2008 May 19]
- 12.US FDA. Bayer voluntarily withdraws Baycol. FDA Talk Papers 2001 Aug 8 [online]. Available from URL: http://www.f-da.gov/bbs/topics/ANSWERS/2001/ANS01095.html [Accessed 2008 May 14]
- 19.Italian Ministry of Health. Dear Doctor letter on nimesulide. Bollettino di Informazione sui Farmaci Genn 2002 Apr [online]. Available from URL: http://www.agenziafarmaco.it/wscs_render_attachment_by_id/111.33840.1150359346504a37e.pdf?.html [Accessed 2007 Sep 28]
- 20.Irish Medicines Board. Human medicines: urgent recall nimesulide-containing oral products 2007 May 15 [online]. Available from URL: http://www.imb.ie/controls/showpdf.ashx?type=NOTICE&pageid=1943&filename=Human% [Accessed 2008 May 14]
- 21.European Medicines Agency (EMeA). Press release. European Medicines Agency recommends restricted use of nimesulide-containing medicinal products [online]. Available from URL: http://www.emea.europa.eu/pdfs/general/direct/pr/43260407en.pdf [Accessed 2007 Sep 28]
- 23.Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73PubMedCrossRefGoogle Scholar